Arrowhead appoints Sarepta CEO Douglas Ingram as director

ARROWHEAD PHARMACEUTICALS, INC.

Douglas Ingram appointed to Arrowhead board effective Feb 6, 2025, per Investor Rights Agreement with Sarepta.
Ingram is President and CEO of Sarepta, with which Arrowhead has a collaboration agreement from Nov 2024.
He receives standard non-employee director compensation plus sign-on RSUs of $771,200 vesting over 3 years.
Ingram is not independent under Nasdaq rules due to the Sarepta collaboration and stock purchase.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Douglas Ingram

director

ARWR · ARROWHEAD PHARMACEUTICALS, INC.

Effective: 2025-02-06
Filed: February 7, 2025, 6:59 PM ET

On February 5, 2025, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Douglas Ingram as a director of the Company, effective February 6, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Douglas Ingram was appointed as director at ARROWHEAD PHARMACEUTICALS, INC..

Action: appointed
Role: director

Exact text from the filing

On February 5, 2025, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Douglas Ingram as a director of the Company, effective February 6, 2025.

View on SEC.gov

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-25-004313

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.